Last reviewed · How we verify
NCT06230549: ProART
Adaptive Radiotherapy in Patients With Gynecological Tumors
NA trial testing Adaptive Radiotherapy in Gynecological Tumor in 30 participants. Currently enrolling.
15 December 2024
Quick facts
| Lead sponsor | University Hospital, Essen |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 January 2024 |
| Primary completion | 15 December 2024 |
| Estimated completion | 15 December 2026 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Adaptive Radiotherapy
Conditions studied
- Gynecological Tumor — all drugs for Gynecological Tumor →
- Adaptive Radiotherapy — all drugs for Adaptive Radiotherapy →
- Radiation — all drugs for Radiation →
- Curative Treatment — all drugs for Curative Treatment →
Sponsor
University Hospital, Essen
Who can join
18 and older, female only, with Gynecological Tumor or Adaptive Radiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective randomized evaluation of adaptive radiotherapy in the definitive radiotherapy of locally advanced gynecologic carcinoma (e.g. cervical carcinoma, endometrial carcinoma, vaginal carcinoma), in the postoperative situation or first series of external beam radiotherapy and in patients in whom radical surgery or HDR brachytherapy as dose boost is not an option.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06230549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Adaptive Radiotherapy
Trials testing the same drug.
- NCT06216171 — Adaptive Radiotherapy in Head and Neck Tumor Patients · NA · recruiting
- NCT06214611 — Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors · NA · recruiting
- NCT05081531 — AI for Head Neck Cancer Treated With Adaptive RadioTherapy (RadiomicART) · NA · active not recruiting
- NCT04242459 — Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers · Phase 1, PHASE2 · unknown
- NCT03096808 — Adaptive Radiotherapy for Head and Neck Cancer · Phase 2 · completed
Other University Hospital, Essen trials
Trials by the same sponsor.
- NCT07409584 — Mental Health and Suicidality in Glioblastoma Patients in Germany · recruiting
- NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
- NCT06388369 — Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer · Phase 1, PHASE2 · terminated
- NCT07130526 — Distrupt Stiffness Trial · NA · recruiting
- NCT07343466 — Quality of Life and the Influence of Stress on the Postoperative Course of Patients After Device Implantation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06230549 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Essen
- Last refreshed: 9 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06230549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing